US 12,233,079 B2
Composition and method for treating humans using low-fodmap diets
Bruce McConnell, La Tour de Peilz (CH); and Louise Kristine Vigsnæs, Copenhagen NV (DK)
Assigned to Glycom A/S, Hørsholm (DK)
Appl. No. 17/417,029
Filed by Glycom A/S, Hørsholm (DK)
PCT Filed Dec. 19, 2019, PCT No. PCT/IB2019/061096
§ 371(c)(1), (2) Date Jun. 21, 2021,
PCT Pub. No. WO2020/128947, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. PA201801022 (DK), filed on Dec. 19, 2018.
Prior Publication US 2022/0072017 A1, Mar. 10, 2022
Int. Cl. A61K 31/702 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01); A61K 35/20 (2006.01); A61K 47/24 (2006.01); A61K 47/38 (2006.01); A61K 47/42 (2017.01); A61K 47/44 (2017.01); A61P 1/14 (2006.01)
CPC A61K 31/702 (2013.01) [A61K 9/0095 (2013.01); A61K 9/1611 (2013.01); A61K 9/1688 (2013.01); A61K 9/4825 (2013.01); A61K 35/20 (2013.01); A61K 47/24 (2013.01); A61K 47/38 (2013.01); A61K 47/42 (2013.01); A61K 47/44 (2013.01); A61P 1/14 (2018.01)] 13 Claims
 
1. A method comprising:
providing to a non-infant human consuming a low-FODMAP diet for reducing gastrointestinal symptoms incident to a diagnosis of irritable bowel syndrome (IBS) made after excluding confounding conditions comprising lactose intolerance and celiac disease, a composition comprising a dosage of one or more neutral human milk oligosaccharides (HMOs), the composition formulated for permitting subsequent or concurrent reintroduction of FODMAPs into a diet without inducing gastrointestinal symptoms in the non-infant human and increasing a relative abundance of adult-type bifidobacteria endogenous to the colon of the non-infant human, wherein the reintroduced FODMAPs contain one or more of: fructans, galactooligosaccharides (GOS), fructose, and/or polyols; and
providing instructions to reintroduce a suitable source of the FODMAPs into the diet of the non-infant human after or during consumption of the composition comprising the dosage of the one or more neutral HMOs during an initial phase, wherein the suitable source of the FODMAPS is reintroduced into the diet of the non-infant human without an increase in levels of the one or more gastrointestinal symptoms relative to levels prior to beginning the initial phase.